Atrion Corporation Announces Quarterly Dividend of $1.20 (ATRI)
Atrion Corporation (NASDAQ:ATRI) announced a quarterly dividend on Thursday, November 9th, Wall Street Journal reports. Investors of record on Friday, December 1st will be paid a dividend of 1.20 per share by the medical instruments supplier on Friday, December 15th. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend is Thursday, November 30th.
Atrion Corporation has raised its dividend payment by an average of 17.6% per year over the last three years and has raised its dividend annually for the last 14 consecutive years.
Shares of Atrion Corporation (NASDAQ:ATRI) opened at $645.05 on Friday. Atrion Corporation has a 12 month low of $433.95 and a 12 month high of $694.00. The firm has a market cap of $1,200.46, a price-to-earnings ratio of 38.52 and a beta of 0.86.
Atrion Corporation (NASDAQ:ATRI) last released its earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share for the quarter. Atrion Corporation had a net margin of 22.98% and a return on equity of 18.64%. The firm had revenue of $37.90 million during the quarter.
TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/10/atrion-corporation-announces-quarterly-dividend-of-1-20-atri.html.
In related news, Chairman Emile A. Battat sold 1,408 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $652.91, for a total value of $919,297.28. Following the completion of the sale, the chairman now owns 148,881 shares of the company’s stock, valued at $97,205,893.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 23.10% of the company’s stock.
Separately, BidaskClub downgraded shares of Atrion Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th.
About Atrion Corporation
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Stock Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related stocks with our FREE daily email newsletter.